Syndax Pharmaceuticals, Inc. (SNDX) Q2 FY26 Earnings Call

Commercial momentum and longer treatment duration support growth, but new-start variability remains the key near-term execution risk.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-04
Length67 minutes
EPS$-0.55
EPS consensus$-0.45
Revenue$72.8M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25 · Q2 FY25

All SNDX earnings · Back to SNDX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.